dc.contributor.author | Namal, Esat | |
dc.contributor.author | Sener, Nur | |
dc.contributor.author | Ulas, Turgay | |
dc.contributor.author | Akcali, Zafer | |
dc.contributor.author | Oztekin, Erkan | |
dc.contributor.author | Borlu, Fatih | |
dc.date.accessioned | 2019-08-13T12:10:23Z | |
dc.date.accessioned | 2019-08-13T16:03:54Z | |
dc.date.available | 2019-08-13T12:10:23Z | |
dc.date.available | 2019-08-13T16:03:54Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 1302-8723 | |
dc.identifier.uri | https://dx.doi.org/10.5152/akd.2011.192 | |
dc.identifier.uri | http://hdl.handle.net/11446/3192 | |
dc.description | WOS: 000298576700009 | en_US |
dc.description | PubMed ID: 22088858 | en_US |
dc.description.abstract | Objective: The aim of our study was to evaluate the effects of two different statins and a statin/ezetimibe combination on high sensitive C-reactive protein (hsCRP) values, which were given at high doses in the early period of acute coronary syndromes. Methods: A total of 150 patients with non-ST elevation myocardial infarction and unstable angina pectoris were enrolled to our prospective, randomized, single-blind study. Patients were divided into three groups by block randomization method. One group received 20mg/day atorvastatin, one group received 10 mg/day rosuvastatin and the other group received 10 mg/day ezetimibe/simvastatin combination therapy, which was initiated within the first 24 hours of admission. Follow-up duration was 2 months. Biochemical investigations and hsCRP levels (by nephelometric method) were performed with 138 patients evaluated at baseline, 10(th) and 60(th) days of therapy. Decreases of hsCRP levels were analyzed with one-way MANOVA and repeated measures of ANOVA methods. Post-hoc Tukey HSD test was performed for finding the different group, when the difference was detected between the groups. Results: Tenth day hsCRP levels in ezetimibe/simvastatin group was significantly lower than the other groups (p<0.001). Further, after 60 days of follow-up a significant reduction was seen in hsCRP levels in ezetimib/simvastatin group (in ezetimibe/simvastatin group the mean hsCRP was reduced from 38.4 +/- 15.0 mg/L to 2.4 +/- 1.3 mg/L, in atorvastatin group the mean hsCRP was reduced from 27.3 +/- 11.7 mg/L to 4.1 +/- 2.4 mg/L and in rosuvastatin group the mean hsCRP was reduced from 22.0 +/- 6.9 mg/L to 3.6 +/- 1.7 mg/L (F (1.1, 148.2) = 746.9, p<0.01 and the difference between drugs; F (2.2, 148.2) = 32.1, p<0.01). No side effects related to drugs were seen during follow-up in all three treatment groups. Conclusion: This study showed that ezetimibe/simvastatin 10 mg/day combination treatment was superior to atorvastatin 20 mg/day and rosuvastatin 10 mg/day treatment in reducing the inflammatory markers when high dose statins was started in the early period of unstable angina and non ST elevation myocardial infarction. (Anadolu Kardiyol Derg 2011; 11: 703-10) | en_US |
dc.language.iso | tur | en_US |
dc.publisher | AVES YAYINCILIK | en_US |
dc.identifier.doi | 10.5152/akd.2011.192 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Acute coronary syndrome | en_US |
dc.subject | statins | en_US |
dc.subject | treatment | en_US |
dc.subject | C - reactive protein | en_US |
dc.subject | lipids | en_US |
dc.title | Effects of different statins, ezetimibe/simvastatin combination On hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial | en_US |
dc.type | article | en_US |
dc.relation.journal | ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.startpage | 703 | en_US |
dc.identifier.endpage | 710 | en_US |
dc.contributor.authorID | 0000-0003-2473-4431 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Ulas, Turgay] Harran Univ, Tip Fak, Ic Hastaliklan Anabilim Dali, Sanliurfa, Turkey -- [Namal, Esat -- Akcali, Zafer] Bilim Univ, Tip Fak, Tibbi Onkol Bilim Dalt, Istanbul, Turkey -- [Sener, Nur] Kartal Egitim Arastirma Hastanesi, Tibbi Onkol Bilim Dalt, Istanbul, Turkey -- [Oztekin, Erkan] Sisli Etfal Egitim & Arastirma Hastanesi, Istanbul, Turkey | en_US |